<DOC>
	<DOC>NCT01511874</DOC>
	<brief_summary>The purpose of this study is to evaluate efficacy and safety of ELIGARD 22.5mg in the treatment of subjects with prostate cancer.</brief_summary>
	<brief_title>Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Male of 20 years or above Subject with prostate cancer with TNM stage T2~4NxMx Blood testosterone concentration ≥ 100ng/dl Bilirubin ≤ 1.5xULN, transaminase ≤ 2.5xULN WHO ECOG performance status ≤ 2 Signed written informed consent HormoneRefractory Prostate cancer Brain metastasis Another primary malignant tumor except for prostate cancer Other conditions which in the opinion of the investigator preclude enrollment into the study</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>ELIGARD</keyword>
	<keyword>Prostate cancer</keyword>
</DOC>